Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06585410 · ClinicalTrials.gov registry record · Phase 3
Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma
A Phase 3 study of Cutaneous Squamous Cell Carcinoma (CSCC), sponsored by Regeneron Pharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 369
- Enrollment target
- 20
- Study locations
NCT06585410: Recruiting Phase 3 study of Cutaneous Squamous Cell Carcinoma (CSCC), sponsored by Regeneron Pharmaceuticals.
NCT06585410 is a Phase 3 study of Cutaneous Squamous Cell Carcinoma (CSCC) that is actively recruiting participants, run by Regeneron Pharmaceuticals. The registered enrollment target is 369 participants, above the 95-participant average among 4 other Cutaneous Squamous Cell Carcinoma (CSCC) trials with a reported enrollment target (288% higher). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06585410, a Phase 3 study of Cutaneous Squamous Cell Carcinoma (CSCC), is actively recruiting participants, sponsored by Regeneron Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 369 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will test a study drug called cemiplimab to see if it can help treat early-stage cutaneous squamous cell carcinoma (CSCC), a type of skin cancer. Cemiplimab works by helping the immune system to kill cancer cells. It binds to a protein called programmed cell death-1 (PD-1) on the surface of certain immune cells. The main purpose of this study is to compare how well cemiplimab works compared to surgery, when injected into the lesion. The study is looking at: * The side effects cemiplimab might cause * How well cemiplimab works
Conditions Studied
Interventions
- DRUG Cemiplimab
- PROCEDURE Standard of care
Study Locations (20)
Arizona
- Medical Dermatology Specialists - Phoenix
- Mayo Clinic - Arizona - Scottsdale
- University of Arizona Cancer Center - Tucson
California
- UC San Diego Moores Cancer Center - La Jolla
- Stanford University - Redwood City
- Peak Dermatology, Aesthetics and Wellness - Visalia
Florida
- Life Clinical Trials - Coral Springs
- Dermatology Associates of the Palm Beaches - Delray Beach
- University of South Florida - St. Petersburg
Illinois
- University of Chicago Medical Center - Chicago
- Oak Dermatology - Naperville
Massachusetts
- Northeast Dermatology Associates - Beverly
- Dana-Farber Cancer Institute - Boston
Michigan
- MyMichigan Dermatologic Oncology - Midland
- Somerset Skin Centre - Troy
Arkansas
- Arkansas Research Trials - North Little Rock
District of Columbia
- George Washington University Medical Faculty Associates - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 369 participants |
| Start Date | 2025-01-02 |
| Est. Completion | 2030-05-03 |
| Phase | Phase 3 |
What NCT06585410 shows while recruiting
NCT06585410 is an interventional study that assigns participants to a tested intervention. The registered 369 participants enrollment target is mid-sized for trials with a published cap, above the 95-participant average among 4 other Cutaneous Squamous Cell Carcinoma (CSCC) trials with a reported enrollment target (288% higher).
The record links to 1 condition, with Cutaneous Squamous Cell Carcinoma (CSCC) appearing as the primary indexed condition, and to 2 interventions - of which Cemiplimab is the first listed.
NCT06585410 names 20 study sites across 11 states, led by Arizona, California, Florida.
Frequently Asked Questions
What is clinical trial NCT06585410 about?
NCT06585410 is a clinical study titled "Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma". This study will test a study drug called cemiplimab to see if it can help treat early-stage cutaneous squamous cell carcinoma (CSCC), a type of skin cancer. Cemiplimab works by helping the immune system to kill cancer cells. It binds to a protein called programmed cell death-1 (PD-1) on the surface ...
What is the current status of trial NCT06585410?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 369 participants. The study started on 2025-01-02. Estimated completion is 2030-05-03.
What conditions does trial NCT06585410 study?
This clinical trial studies the following conditions: Cutaneous Squamous Cell Carcinoma (CSCC).
What interventions are being tested in trial NCT06585410?
The interventions under investigation include: Cemiplimab (DRUG), Standard of care (PROCEDURE).
Who is sponsoring clinical trial NCT06585410?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06585410 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cutaneous Squamous Cell Carcinoma (CSCC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Liquid Biomarker Study in Melanoma and Non-Melanoma Skin Cancers
RECRUITING
-
A Phase 0 Window of Opportunity Trial of Intratumoral Seasonal Influenza Immunization in Cutaneous Squamous Cell Carcinoma (CSCC) Patients Awaiting Curative Excision
RECRUITING · Early Phase 1
-
Tumor-Informed ctDNA Testing for MRD Following Treatment of Squamous Cell Carcinoma
RECRUITING
-
Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06114836 · 369 participants · NA
GERD Infant Feeding Therapeutics Trial (GIFT Trial)
- NCT07256717 · 369 participants · NA
BPIT 5-Week Multi-Site Study: Movement Efficiency, Mobility & Neuromuscular Adaptation
- NCT02332668 · 370 participants · Phase 1
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
- NCT04284436 · 370 participants · NA
Study in Parkinson Disease of Exercise
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI